The basic strategy is to obtain a reagent focusing its activity prevalently around the cells expressing CD38, which enables avidity-induced blocking of CD47 on the same cells, in this way avoiding unwanted off-tumor effects. The gene discussed is CD38; the disease is neoplasm.